

Bert A 't Hart

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2411915/publications.pdf>

Version: 2024-02-01

58
papers

2,457
citations

172457

29
h-index

206112

48
g-index

59
all docs

59
docs citations

59
times ranked

2396
citing authors

#	ARTICLE	IF	CITATIONS
1	Transfer of Central Nervous System Autoantigens and Presentation in Secondary Lymphoid Organs. <i>Journal of Immunology</i> , 2002, 169, 5415-5423.	0.8	256
2	Histopathological Characterization of Magnetic Resonance Imaging-Detectable Brain White Matter Lesions in a Primate Model of Multiple Sclerosis. <i>American Journal of Pathology</i> , 1998, 153, 649-663.	3.8	145
3	EAE: imperfect but useful models of multiple sclerosis. <i>Trends in Molecular Medicine</i> , 2011, 17, 119-125.	6.7	145
4	Myelin/Oligodendrocyte Glycoprotein-Induced Autoimmune Encephalomyelitis in Common Marmosets: The Encephalitogenic T Cell Epitope pMOG24â€“36 Is Presented by a Monomorphic MHC Class II Molecule. <i>Journal of Immunology</i> , 2000, 165, 1093-1101.	0.8	123
5	Surgical excision of CNSâ€“draining lymph nodes reduces relapse severity in chronicâ€“relapsing experimental autoimmune encephalomyelitis. <i>Journal of Pathology</i> , 2009, 217, 543-551.	4.5	112
6	The marmoset monkey: a multi-purpose preclinical and translational model of human biology and disease. <i>Drug Discovery Today</i> , 2012, 17, 1160-1165.	6.4	97
7	Induction of Progressive Demyelinating Autoimmune Encephalomyelitis in Common Marmoset Monkeys Using MOG₃₄₋₅₆Peptide in Incomplete Freund Adjuvant. <i>Journal of Neuropathology and Experimental Neurology</i> , 2010, 69, 372-385.	1.7	74
8	Native myelin oligodendrocyte glycoprotein promotes severe chronic neurological disease and demyelination in Biozzi ABH mice. <i>European Journal of Immunology</i> , 2005, 35, 1311-1319.	2.9	64
9	Fast Progression of Recombinant Human Myelin/Oligodendrocyte Glycoprotein (MOG)-Induced Experimental Autoimmune Encephalomyelitis in Marmosets Is Associated with the Activation of MOG34â€“56-Specific Cytotoxic T Cells. <i>Journal of Immunology</i> , 2008, 180, 1326-1337.	0.8	61
10	Modulation of Multiple Sclerosis and Its Animal Model Experimental Autoimmune Encephalomyelitis by Food and Gut Microbiota. <i>Frontiers in Immunology</i> , 2017, 8, 1081.	4.8	61
11	Cytomegalovirus: a culprit or protector in multiple sclerosis?. <i>Trends in Molecular Medicine</i> , 2015, 21, 16-23.	6.7	60
12	Survival and Functionality of Human Induced Pluripotent Stem Cell-Derived Oligodendrocytes in a Nonhuman Primate Model for Multiple Sclerosis. <i>Stem Cells Translational Medicine</i> , 2016, 5, 1550-1561.	3.3	57
13	Multiple sclerosis â€“ a response-to-damage model. <i>Trends in Molecular Medicine</i> , 2009, 15, 235-244.	6.7	54
14	Late B Cell Depletion with a Human Anti-Human CD20 IgG1Î² Monoclonal Antibody Halts the Development of Experimental Autoimmune Encephalomyelitis in Marmosets. <i>Journal of Immunology</i> , 2010, 185, 3990-4003.	0.8	53
15	Unravelling the Tâ€“cellâ€“mediated autoimmune attack on CNS myelin in a new primate EAE model induced with MOG_{34â€“56} peptide in incomplete adjuvant. <i>European Journal of Immunology</i> , 2012, 42, 217-227.	2.9	52
16	EBV Infection Empowers Human B Cells for Autoimmunity: Role of Autophagy and Relevance to Multiple Sclerosis. <i>Journal of Immunology</i> , 2017, 199, 435-448.	0.8	52
17	The human CMV-UL86 peptide 981â€“1003 shares a crossreactive T-cell epitope with the encephalitogenic MOG peptide 34â€“56, but lacks the capacity to induce EAE in rhesus monkeys. <i>Journal of Neuroimmunology</i> , 2007, 182, 135-152.	2.3	51
18	Induction of Experimental Autoimmune Encephalomyelitis With Recombinant Human Myelin Oligodendrocyte Glycoprotein in Incomplete Freundâ€™s Adjuvant in Three Non-human Primate Species. <i>Journal of NeuroImmune Pharmacology</i> , 2013, 8, 1251-1264.	4.1	49

#	ARTICLE	IF	CITATIONS
19	Bacterial Peptidoglycan as a Driver of Chronic Brain Inflammation. <i>Trends in Molecular Medicine</i> , 2020, 26, 670-682.	6.7	49
20	The Primate EAE Model Points at EBV-Infected B Cells as a Preferential Therapy Target in Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2013, 4, 145.	4.8	48
21	Autoimmunity Against Myelin Oligodendrocyte Glycoprotein Is Dispensable for the Initiation Although Essential for the Progression of Chronic Encephalomyelitis in Common Marmosets. <i>Journal of Neuropathology and Experimental Neurology</i> , 2008, 67, 326-340.	1.7	47
22	The primate autoimmune encephalomyelitis model; a bridge between mouse and man. <i>Annals of Clinical and Translational Neurology</i> , 2015, 2, 581-593.	3.7	47
23	Apocynin, a Low Molecular Oral Treatment for Neurodegenerative Disease. <i>BioMed Research International</i> , 2014, 2014, 1-6.	1.9	45
24	Lymphocryptovirus Infection of Nonhuman Primate B Cells Converts Destructive into Productive Processing of the Pathogenic CD8 T Cell Epitope in Myelin Oligodendrocyte Glycoprotein. <i>Journal of Immunology</i> , 2016, 197, 1074-1088.	0.8	41
25	Axon-Myelin Unit Blistering as Early Event in <sc>MS</sc> Normal Appearing White Matter. <i>Annals of Neurology</i> , 2021, 89, 711-725.	5.3	39
26	Antibodies Against Human BlyS and APRIL Attenuate EAE Development in Marmoset Monkeys. <i>Journal of NeuroImmune Pharmacology</i> , 2012, 7, 557-570.	4.1	34
27	B-Cell Depletion Attenuates White and Gray Matter Pathology in Marmoset Experimental Autoimmune Encephalomyelitis. <i>Journal of Neuropathology and Experimental Neurology</i> , 2011, 70, 992-1005.	1.7	33
28	An Overview of Models, Methods, and Reagents Developed for Translational Autoimmunity Research in the Common Marmoset (<i>Callithrix jacchus&/i>). <i>Experimental Animals</i> , 2013, 62, 159-171.	1.1	33
29	B-Cell Depletion Abrogates T Cell-Mediated Demyelination in an Antibody-Nondependent Common Marmoset Experimental Autoimmune Encephalomyelitis Model. <i>Journal of Neuropathology and Experimental Neurology</i> , 2012, 71, 716-728.	1.7	32
30	The Different Clinical Effects of Anti-BlyS, Anti-APRIL and Anti-CD20 Antibodies Point at a Critical Pathogenic Role of Î³-Herpesvirus Infected B Cells in the Marmoset EAE Model. <i>Journal of NeuroImmune Pharmacology</i> , 2013, 8, 727-738.	4.1	32
31	Immune profile of an atypical EAE model in marmoset monkeys immunized with recombinant human myelin oligodendrocyte glycoprotein in incomplete Freund's adjuvant. <i>Journal of Neuroinflammation</i> , 2015, 12, 169.	7.2	30
32	Targeted Diet Modification Reduces Multiple Sclerosis-like Disease in Adult Marmoset Monkeys from an Outbred Colony. <i>Journal of Immunology</i> , 2018, 201, 3229-3243.	0.8	29
33	CD20+ B Cell Depletion Alters T Cell Homing. <i>Journal of Immunology</i> , 2014, 192, 4242-4253.	0.8	24
34	Embracing Complexity beyond Systems Medicine: A New Approach to Chronic Immune Disorders. <i>Frontiers in Immunology</i> , 2016, 7, 587.	4.8	24
35	The common marmoset as an indispensable animal model for immunotherapy development in multiple sclerosis. <i>Drug Discovery Today</i> , 2016, 21, 1200-1205.	6.4	22
36	Multiple sclerosis is linked to MAPK<small>ERK&/small> overactivity in microglia. <i>Journal of Molecular Medicine</i> , 2021, 99, 1033-1042.	3.9	22

#	ARTICLE	IF	CITATIONS
37	Blockade of CD127 Exerts a Dichotomous Clinical Effect in Marmoset Experimental Autoimmune Encephalomyelitis. <i>Journal of NeuroImmune Pharmacology</i> , 2016, 11, 73-83.	4.1	20
38	Mechanistic underpinning of an inside-out concept for autoimmunity in multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1709-1719.	3.7	20
39	Chronic autoimmune-mediated inflammation: a senescent immune response to injury. <i>Drug Discovery Today</i> , 2013, 18, 372-379.	6.4	19
40	A B Cell-Driven Autoimmune Pathway Leading to Pathological Hallmarks of Progressive Multiple Sclerosis in the Marmoset Experimental Autoimmune Encephalomyelitis Model. <i>Frontiers in Immunology</i> , 2017, 8, 804.	4.8	19
41	The translational value of non-human primates in preclinical research on infection and immunopathology. <i>European Journal of Pharmacology</i> , 2015, 759, 69-83.	3.5	18
42	Analysis of the cross-talk of Epstein-Barr virus-infected B cells with T cells in the marmoset. <i>Clinical and Translational Immunology</i> , 2017, 6, e127.	3.8	18
43	Reverse translation of failed treatments can help improving the validity of preclinical animal models. <i>European Journal of Pharmacology</i> , 2015, 759, 14-18.	3.5	13
44	Intradermal vaccination prevents anti-MOG autoimmune encephalomyelitis in macaques. <i>EBioMedicine</i> , 2019, 47, 492-505.	6.1	13
45	Tissue Transglutaminase in Marmoset Experimental Multiple Sclerosis: Discrepancy between White and Grey Matter. <i>PLoS ONE</i> , 2014, 9, e100574.	2.5	13
46	Editorial: Inside-Out vs Outside-In Paradigms in Multiple Sclerosis Etiopathogenesis. <i>Frontiers in Cellular Neuroscience</i> , 2021, 15, 666529.	3.7	12
47	Severe oxidative stress in an acute inflammatory demyelinating model in the rhesus monkey. <i>PLoS ONE</i> , 2017, 12, e0188013.	2.5	12
48	Amyloid-like Behavior of Site-Specifically Citrullinated Myelin Oligodendrocyte Protein (MOG) Peptide Fragments inside EBV-Infected B-Cells Influences Their Cytotoxicity and Autoimmunogenicity. <i>Biochemistry</i> , 2019, 58, 763-775.	2.5	11
49	Induction of Encephalitis in Rhesus Monkeys Infused with Lymphocryptovirus-Infected B-Cells Presenting MOG34-56 Peptide. <i>PLoS ONE</i> , 2013, 8, e71549.	2.5	11
50	Experimental autoimmune encephalomyelitis in the common marmoset: a translationally relevant model for the cause and course of multiple sclerosis. <i>Primate Biology</i> , 2019, 6, 17-58.	1.0	11
51	Reverse Translation for Assessment of Confidence in Animal Models of Multiple Sclerosis for Drug Discovery. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 262-270.	4.7	9
52	Multiple sclerosis and drug discovery: A work of translation. <i>EBioMedicine</i> , 2021, 68, 103392.	6.1	9
53	Nutritional and ecological perspectives of the interrelationships between diet and the gut microbiome in multiple sclerosis: Insights from marmosets. <i>IScience</i> , 2021, 24, 102709.	4.1	9
54	Merits and complexities of modeling multiple sclerosis in non-human primates: implications for drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2018, 13, 387-397.	5.0	8

#	ARTICLE	IF	CITATIONS
55	New drug discovery strategies for rheumatoid arthritis: a niche for nonhuman primate models to address systemic complications in inflammatory arthritis. <i>Expert Opinion on Drug Discovery</i> , 2012, 7, 315-325.	5.0	5
56	A Tolerogenic Role of Cathepsin G in a Primate Model of Multiple Sclerosis: Abrogation by Epstein-Barr Virus Infection. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2020, 68, 21.	2.3	5
57	The Forgotten Brother: The Innate-like B1 Cell in Multiple Sclerosis. <i>Biomedicines</i> , 2022, 10, 606.	3.2	4
58	Recombinant myelin oligodendrocyte glycoprotein quality modifies evolution of experimental autoimmune encephalitis in macaques. <i>Laboratory Investigation</i> , 2021, 101, 1513-1522.	3.7	1